Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2012 02:30 ET | Source: Active Biotech

Tasquinimod Biomarker Phase II data presented at ESMO 2012

Lund (Sweden) and Paris (France), October 1, 2012. Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) have presented a new set of data on biomarkers from the previously...
October 01, 2012 02:30 ET | Source: Active Biotech

Tasquinimod biomarkörsdata från fas II presenterade på ESMO 2012

Lund och Paris (Frankrike) den 1 oktober, 2012. Active Biotech (NASDAQ OMX NORDIC: ACTI) och Ipsen (Euronext: IPN; ADR: IPSEY) har på den vetenskapliga konferensen ESMO (European Society for Medical...
September 06, 2012 02:30 ET | Source: Active Biotech

Active Biotech presenterar på Rodman & Renshaw Annual Global Investment Conference

Lund den 6 september 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) kommer att presentera företaget på konferensen Rodman & Renshaw Annual Global Investment Conference som hålls den 9-11...
September 06, 2012 02:30 ET | Source: Active Biotech

Active Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference

Lund, Sweden, September 6, 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is scheduled to present at the Rodman & Renshaw Annual Global Investment Conference held September 9-11, 2012 in New...
August 10, 2012 02:30 ET | Source: Active Biotech

Active Biotech AB Delårsrapport januari - juni 2012

Laquinimod - registreringsansökan inlämnad i EU vilket medför delmålsbetalning om 5 MUSD under tredje kvartalet 2012 - fas III-studie initieras i USA TASQ -...
August 10, 2012 02:30 ET | Source: Active Biotech

Active Biotech AB Interim report January - June 2012

Laquinimod - application submitted for regulatory approval in the EU resulting in milestone payment of USD 5 M during third quarter 2012 - a Phase III study...
August 08, 2012 08:00 ET | Source: Active Biotech

TEVA PÅBÖRJAR EN TREDJE FAS III-STUDIE MED LAQUINIMOD I TABLETTFORM FÖR BEHANDLING AV RELAPSERANDE REMITTERANDE MULTIPEL SKLEROS

Det kliniska protokollet har erhållit ett "Special Protocol Assessment" (SPA) avtal av det amerikanska läkemedelsverket FDA Lund, Sverige och Jerusalem, Israel den 8 augusti, 2012 - Teva...
August 08, 2012 08:00 ET | Source: Active Biotech

TEVA TO INITIATE THIRD PHASE III TRIAL OF ORAL LAQUINIMOD FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS

The clinical trial protocol has been granted a Special Protocol Assessment agreement by the Food and Drug Administration Jerusalem, Israel and Lund, Sweden, August 8, 2012 - Teva Pharmaceutical...
July 17, 2012 02:30 ET | Source: Active Biotech

ACTIVE BIOTECH MEDDELAR ATT DET EUROPEISKA LÄKEMEDELSVERKET ACCEPTERAT REGISTRERINGSANSÖKAN AV LAQUINIMOD FÖR BEHANDLING AV RELAPSERANDE REMITTERANDE MS OCH UTVÄRDERINGSPROCESSEN PÅBÖRJAS

Lund den 17 juli, 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) meddelar idag att det europeiska läkemedelsverket (EMA) fullföljt valideringsprocessen av registreringsansökan (MAA) för den...
July 17, 2012 02:30 ET | Source: Active Biotech

ACTIVE BIOTECH ANNOUNCE THAT EUROPEAN MEDICINES AGENCY ACCEPTS START OF SCIENTIFIC REVIEW OF THE MARKETING AUTHORIZATION APPLICATION FOR LAQUINIMOD IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

Lund, Sweden, July 17, 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced that the European Medicines Agency (EMA) has completed the validation process for the marketing authorization...